"With the capital restructuring of AMBS nearing its final stages, we believe we will soon be positioned to properly execute upon our Elto Pharma strategy. Ultimately, we see value not only from the PD-LID orphan indication for eltoprazine, which we expect to appreciate significantly over time as the PD-LID indication is further clinically de-risked, but we also intend to see the Agitation in Alzheimer's disease and Adult ADHD indications for Eltoprazine become valued by the market as Elto Pharma executes upon its clinical development strategy."